TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Xvivo Perfusion AB ( (SE:XVIVO) ) has shared an announcement.
XVIVO Perfusion AB has been awarded the 2025 SACC-USA Business Award for its innovative contributions and growth in the U.S. market, particularly in organ perfusion and preservation technologies. This recognition underscores XVIVO’s significant impact on the U.S. healthcare system by addressing the growing demand for organ transplants and highlights the company’s role in strengthening Swedish-American business ties through its life-saving innovations.
The most recent analyst rating on (SE:XVIVO) stock is a Sell with a SEK325.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.
More about Xvivo Perfusion AB
Founded in 1998, XVIVO Perfusion AB is a medical technology company focused on extending the life of major organs to aid transplant teams globally in saving more lives. Headquartered in Gothenburg, Sweden, with offices and research sites on two continents, XVIVO is listed on Nasdaq Stockholm and is dedicated to advancing transplantation medicine.
Average Trading Volume: 136,385
Current Market Cap: SEK10.05B
Learn more about XVIVO stock on TipRanks’ Stock Analysis page.